Navigation Links
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Date:1/28/2009

LUGANO, Switzerland, January 28 /PRNewswire/ -- Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed amount.

The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group's corporate strategic goals. "We are thrilled at this very important opportunity to increase Helsinn's value with a direct presence in the major pharmaceutical market of the world," said Riccardo Braglia, CEO of the Helsinn Group. "The acquisition of Sapphire Therapeutics will also allow us to expand our current pipeline of products in existing, focused therapeutic areas, in particular in Cancer Supportive Care. This is a major step forward for the growth of Helsinn into the future with the new subsidiary Helsinn Therapeutics (US) Inc.," he concluded.

Sapphire Therapeutics Inc. was founded in 2000 and is focused on developing first-in-class, composition-of-matter protected products for the treatment of a variety of cancer, gastrointestinal and metabolic conditions. "Sapphire Therapeutics Inc. and its staff have proven pharma and biotech expertise and all of us are extremely excited of becoming part of the Helsinn Group," commented William J. Polvino, CEO of Sapphire Therapeutics (US) Inc.

Helsinn has appointed Franco De Vecchi, who is already a member of Helsinn Holding's Board, to become Chairman and President of Helsinn Therapeutics (US) Inc. to manage all of the existing staff who will be maintained and strengthened.

This acquisition will give the Helsinn Group access to a very interesting and promising pipeline of products:

- anamorelin, a first-in-class therapy for the treatment of cancer cachexia, suitable for once-a-day oral administration, with early evidence of a rapid onset of beneficial effects (appetite, gain weight, quality of life) and a good safety and tolerability profile (end Phase II);

- ipamorelin, for the i.v. treatment of post operative ileus, the impairment of bowel motility following surgery, an unmet medical need (Phase II);

- ST-1141, a new oral compound, for the treatment of opioid-induced bowel dysfunction (Phase I);

- Other products at research stage.

The acquisition will have a direct, positive impact on the Helsinn Group since the production of Helsinn Therapeutics (US) Inc. products will be manufactured in Helsinn's high standard quality manufacturing facilities in Switzerland which operate according to EU and FDA health and environmental requirements.

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland. Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC) development, to the filing for and attainment of their market approval worldwide.

Helsinn's products are sold directly, through the Group subsidiaries, or eventually out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.

The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers.

Helsinn is the worldwide licensor of palonosetron, a second generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and of post-operative nausea and vomiting (PONV) in patients with cancer, and of the original nimesulide, a non-steroidal anti-inflammatory drug (NSAID) distributed in more than 50 countries worldwide.

Helsinn, with a workforce of 430 employees in Switzerland and Ireland, reports an expected 2008 turnover of over 279.5 million CHF, covering 75 countries worldwide, with over 20% of this turnover invested in R&D.

    Contact:
    Dr. Riccardo Braglia, CEO
    Helsinn Healthcare SA, Switzerland
    Phone: +41-91-985-21-21
    E-Mail: PBO@helsinn.com



'/>"/>
SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: ... other medical conditions, today announced that Linda Marbán, Ph.D, president ... upcoming investor conferences: Cowen and Company ... 10:00 am ET Boston, MA ... at 9:00 am PT (12:00 pm ET) Dana ...
(Date:2/23/2017)... FRANCISCO , Feb. 23, 2017   ViaCyte, ... Type 1, a not-for-profit advocacy and education group for ... grant from Beyond Type 1 to support ViaCyte,s efforts ... other insulin-requiring diabetes.  For more than ... cell replacement therapies with a focus on the treatment ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):